{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["adaptive immune system", "amyotrophic", "monocyte", "neurodegeneration", "neuroinflammation", "ozone"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "35328829", "DateCompleted": {"Year": "2022", "Month": "04", "Day": "08"}, "DateRevised": {"Year": "2022", "Month": "04", "Day": "08"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2022", "Month": "03", "Day": "21"}], "ELocationID": ["3403", "10.3390/ijms23063403"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "23", "Issue": "6", "PubDate": {"Year": "2022", "Month": "Mar", "Day": "21"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Therapeutic Treatment of Superoxide Dismutase 1 (G93A) Amyotrophic Lateral Sclerosis Model Mice with Medical Ozone Decelerates Trigeminal Motor Neuron Degeneration, Attenuates Microglial Proliferation, and Preserves Monocyte Levels in Mesenteric Lymph Nodes.", "Abstract": {"AbstractText": ["Amyotrophic lateral sclerosis (ALS) is an incurable and lethal neurodegenerative disease in which progressive motor neuron loss and associated inflammation represent major pathology hallmarks. Both the prevention of neuronal loss and neuro-destructive inflammation are still unmet challenges. Medical ozone, an ozonized oxygen mixture (O<sub>3</sub>/O<sub>2</sub>), has been shown to elicit profound immunomodulatory effects in peripheral organs, and beneficial effects in the aging brain. We investigated, in a preclinical drug testing approach, the therapeutic potential of a five-day O<sub>3</sub>/O<sub>2</sub><i>i.p</i>. treatment regime at the beginning of the symptomatic disease phase in the superoxide dismutase (SOD1<sup>G93A</sup>) ALS mouse model. Clinical assessment of SOD1<sup>G93A</sup> mice revealed no benefit of medical ozone treatment over sham with respect to gross body weight, motor performance, disease duration, or survival. In the brainstem of end stage SOD1<sup>G93A</sup> mice, however, neurodegeneration was found decelerated, and SOD1-related vacuolization was reduced in the motor trigeminal nucleus in the O<sub>3</sub>/O<sub>2</sub> treatment group when compared to sham-treated mice. In addition, microglia proliferation was less pronounced in the brainstem, while the hypertrophy of astroglia remained largely unaffected. Finally, monocyte numbers were reduced in the blood, spleen, and mesenteric lymph nodes at postnatal day 60 in SOD1<sup>G93A</sup> mice. A further decrease in monocyte numbers seen in mesenteric lymph nodes from sham-treated SOD1<sup>G93A</sup> mice at an advanced disease stage, however, was prevented by medical ozone treatment. Collectively, our study revealed a select neuroprotective and possibly anti-inflammatory capacity for medical ozone when applied as a therapeutic agent in SOD1<sup>G93A</sup> ALS mice."]}, "AuthorList": [{"Identifier": ["0000-0002-7336-8207"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Anatomy and Cell Biology, Philipps-University, 35037 Marburg, Germany."}], "LastName": "Bette", "ForeName": "Michael", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Anatomy and Cell Biology, Philipps-University, 35037 Marburg, Germany."}, {"Identifier": [], "Affiliation": "Department of Mitochondrial Proteostasis, Max-Planck-Institute for Biology of Ageing, 50931 Cologne, Germany."}], "LastName": "Cors", "ForeName": "Eileen", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Anatomy and Cell Biology, Philipps-University, 35037 Marburg, Germany."}], "LastName": "Kresse", "ForeName": "Carolin", "Initials": "C"}, {"Identifier": ["0000-0003-4473-1959"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Anatomy and Cell Biology, Philipps-University, 35037 Marburg, Germany."}], "LastName": "Sch\u00fctz", "ForeName": "Burkhard", "Initials": "B"}], "GrantList": [{"GrantID": "Sc10/6", "Agency": "Deutsche Gesellschaft f\u00fcr Muskelkranke", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "EC 1.15.1.1", "NameOfSubstance": "Superoxide Dismutase"}, {"RegistryNumber": "EC 1.15.1.1", "NameOfSubstance": "Superoxide Dismutase-1"}], "MeshHeadingList": [{"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Amyotrophic Lateral Sclerosis"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Disease Progression"}, {"QualifierName": ["pathology"], "DescriptorName": "Inflammation"}, {"QualifierName": ["pathology"], "DescriptorName": "Lymph Nodes"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred C57BL"}, {"QualifierName": [], "DescriptorName": "Mice, Transgenic"}, {"QualifierName": [], "DescriptorName": "Microglia"}, {"QualifierName": ["pathology"], "DescriptorName": "Monocytes"}, {"QualifierName": ["pathology"], "DescriptorName": "Nerve Degeneration"}, {"QualifierName": ["pathology"], "DescriptorName": "Neurodegenerative Diseases"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Ozone"}, {"QualifierName": ["genetics", "pharmacology"], "DescriptorName": "Superoxide Dismutase"}, {"QualifierName": ["genetics", "therapeutic use"], "DescriptorName": "Superoxide Dismutase-1"}], "CoiStatement": "The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet. 2011;377:942\u2013955. doi: 10.1016/S0140-6736(10)61156-7.", "ArticleIdList": ["10.1016/S0140-6736(10)61156-7", "21296405"]}, {"Citation": "Millecamps S., Boill\u00e9e S., Le Ber I., Seilhean D., Teyssou E., Giraudeau M., Moigneu C., Vandenberghe N., Danel-Brunaud V., Corcia P., et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J. Med. Genet. 2012;49:258\u2013263. doi: 10.1136/jmedgenet-2011-100699.", "ArticleIdList": ["10.1136/jmedgenet-2011-100699", "22499346"]}, {"Citation": "Chi\u00f2 A., Calvo A., Mazzini L., Cantello R., Mora G., Moglia C., Corrado L., D\u2019Alfonso S., Majounie E., Renton A., et al. Extensive genetics of ALS: A population-based study in Italy. Neurology. 2012;79:1983\u20131989. doi: 10.1212/WNL.0b013e3182735d36.", "ArticleIdList": ["10.1212/WNL.0b013e3182735d36", "PMC3484987", "23100398"]}, {"Citation": "Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O\u2019Regan J.P., Deng H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59\u201362. doi: 10.1038/362059a0.", "ArticleIdList": ["10.1038/362059a0", "8446170"]}, {"Citation": "Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772\u20131775. doi: 10.1126/science.8209258.", "ArticleIdList": ["10.1126/science.8209258", "8209258"]}, {"Citation": "Mancuso R., Navarro X. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog. Neurobiol. 2015;133:1\u201326. doi: 10.1016/j.pneurobio.2015.07.004.", "ArticleIdList": ["10.1016/j.pneurobio.2015.07.004", "26253783"]}, {"Citation": "Henkel J.S., Beers D.R., Wen S., Rivera A.L., Toennis K.M., Appel J.E., Zhao W., Moore D.H., Powell S.Z., Appel S.H. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013;5:64\u201379. doi: 10.1002/emmm.201201544.", "ArticleIdList": ["10.1002/emmm.201201544", "PMC3569654", "23143995"]}, {"Citation": "Hooten K.G., Beers D.R., Zhao W., Appel S.H. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:364\u2013375. doi: 10.1007/s13311-014-0329-3.", "ArticleIdList": ["10.1007/s13311-014-0329-3", "PMC4404435", "25567201"]}, {"Citation": "Geloso M.C., Corvino V., Marchese E., Serrano A., Michetti F., D\u2019Ambrosi N. The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches. Front. Aging. Neurosci. 2017;9:242. doi: 10.3389/fnagi.2017.00242.", "ArticleIdList": ["10.3389/fnagi.2017.00242", "PMC5524666", "28790913"]}, {"Citation": "Zhao W., Beers D.R., Appel S.H. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013;8:888\u2013899. doi: 10.1007/s11481-013-9489-x.", "ArticleIdList": ["10.1007/s11481-013-9489-x", "PMC4126425", "23881705"]}, {"Citation": "Smith N.L., Wilson A.L., Gandhi J., Vatsia S., Khan S.A. Ozone therapy: An overview of pharmacodynamics, current research, and clinical utility. Med. Gas. Res. 2017;7:212\u2013219. doi: 10.4103/2045-9912.215752.", "ArticleIdList": ["10.4103/2045-9912.215752", "PMC5674660", "29152215"]}, {"Citation": "Kelly F.J., Mudway I., Krishna M.T., Holgate S.T. The free radical basis of air pollution: Focus on ozone. Respir. Med. 1995;89:647\u2013656. doi: 10.1016/0954-6111(95)90131-0.", "ArticleIdList": ["10.1016/0954-6111(95)90131-0", "8570878"]}, {"Citation": "Viebahn-Haensler R., Le\u00f3n Fern\u00e1ndez O.S. Ozone in Medicine. The Low-Dose Ozone Concept and Its Basic Biochemical Mechanisms of Action in Chronic Inflammatory Diseases. Int. J. Mol. Sci. 2021;22:7890. doi: 10.3390/ijms22157890.", "ArticleIdList": ["10.3390/ijms22157890", "PMC8346137", "34360655"]}, {"Citation": "Elkholy W.B., Al-Gholam M.A. Role of medical ozone in attenuating age-related changes in the rat cerebellum. Microscopy. 2018;67:214\u2013221. doi: 10.1093/jmicro/dfy017.", "ArticleIdList": ["10.1093/jmicro/dfy017", "29635467"]}, {"Citation": "El-Mehi A.E., Faried M.A. Controlled ozone therapy modulates the neurodegenerative changes in the frontal cortex of the aged albino rat. Ann. Anat. 2020;227:151428. doi: 10.1016/j.aanat.2019.151428.", "ArticleIdList": ["10.1016/j.aanat.2019.151428", "31610254"]}, {"Citation": "Lin S.Y., Ma J., An J.X., Qian X.Y., Wang Y., Cope D.K., Williams J.P. Ozone Inhibits APP/A\u03b2 Production and Improves Cognition in an APP/PS1 Transgenic Mouse Model. Neuroscience. 2019;418:110\u2013121. doi: 10.1016/j.neuroscience.2019.07.027.", "ArticleIdList": ["10.1016/j.neuroscience.2019.07.027", "31349006"]}, {"Citation": "Delgado-Roche L., Riera-Romo M., Mesta F., Hern\u00e1ndez-Matos Y., Barrios J.M., Mart\u00ednez-S\u00e1nchez G., Al-Dalaien S.M. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. Eur. J. Pharmacol. 2017;811:148\u2013154. doi: 10.1016/j.ejphar.2017.06.017.", "ArticleIdList": ["10.1016/j.ejphar.2017.06.017", "28623000"]}, {"Citation": "Tahmasebi S., Qasim M.T., Krivenkova M.V., Zekiy A.O., Thangavelu L., Aravindhan S., Izadi M., Jadidi-Niaragh F., Ghaebi M., Aslani S., et al. The effects of oxygen-ozone therapy on regulatory T-cell responses in multiple sclerosis patients. Cell Biol. Int. 2021;45:1498\u20131509. doi: 10.1002/cbin.11589.", "ArticleIdList": ["10.1002/cbin.11589", "33724614"]}, {"Citation": "Pfohl S.R., Halicek M.T., Mitchell C.S. Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis. J. Neuromuscul. Dis. 2015;2:137\u2013150. doi: 10.3233/JND-140068.", "ArticleIdList": ["10.3233/JND-140068", "PMC4652798", "26594635"]}, {"Citation": "Jaarsma D. Swelling and vacuolisation of mitochondria in transgenic SOD1-ALS mice: A consequence of supranormal SOD1 expression? Mitochondrion. 2006;6:48\u201349. doi: 10.1016/j.mito.2005.10.005.", "ArticleIdList": ["10.1016/j.mito.2005.10.005", "16410057"]}, {"Citation": "Higgins C.M., Jung C., Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci. 2003;4:16. doi: 10.1186/1471-2202-4-16.", "ArticleIdList": ["10.1186/1471-2202-4-16", "PMC169170", "12864925"]}, {"Citation": "Jaarsma D., Rognoni F., van Duijn W., Verspaget H.W., Haasdijk E.D., Holstege J.C. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol. 2001;102:293\u2013305. doi: 10.1007/s004010100399.", "ArticleIdList": ["10.1007/s004010100399", "11603803"]}, {"Citation": "Ringer C., Weihe E., Sch\u00fctz B. SOD1G93A Mutant Mice Develop a Neuroinflammation-Independent Dendropathy in Excitatory Neuronal Subsets of the Olfactory Bulb and Retina. J. Neuropathol. Exp. Neurol. 2017;76:769\u2013778. doi: 10.1093/jnen/nlx057.", "ArticleIdList": ["10.1093/jnen/nlx057", "28859334"]}, {"Citation": "Pryor W.A., Squadrito G.L., Friedman M. The cascade mechanism to explain ozone toxicity: The role of lipid ozonation products. Free Radic. Biol. Med. 1995;19:935\u2013941. doi: 10.1016/0891-5849(95)02033-7.", "ArticleIdList": ["10.1016/0891-5849(95)02033-7", "8582671"]}, {"Citation": "Sagai M., Bocci V. Mechanisms of Action Involved in Ozone Therapy: Is healing induced via a mild oxidative stress? Med. Gas Res. 2011;1:29. doi: 10.1186/2045-9912-1-29.", "ArticleIdList": ["10.1186/2045-9912-1-29", "PMC3298518", "22185664"]}, {"Citation": "Mart\u00ednez-S\u00e1nchez G., Al-Dalain S.M., Men\u00e9ndez S., Re L., Giuliani A., Candelario-Jalil E., Alvarez H., Fern\u00e1ndez-Montequ\u00edn J.I., Le\u00f3n O.S. Therapeutic efficacy of ozone in patients with diabetic foot. Eur. J. Pharmacol. 2005;523:151\u2013161. doi: 10.1016/j.ejphar.2005.08.020.", "ArticleIdList": ["10.1016/j.ejphar.2005.08.020", "16198334"]}, {"Citation": "Re L., Mawsouf M.N., Men\u00e9ndez S., Le\u00f3n O.S., S\u00e1nchez G.M., Hern\u00e1ndez F. Ozone therapy: Clinical and basic evidence of its therapeutic potential. Arch. Med. Res. 2008;39:17\u201326. doi: 10.1016/j.arcmed.2007.07.005.", "ArticleIdList": ["10.1016/j.arcmed.2007.07.005", "18067991"]}, {"Citation": "Re L., Mart\u00ednez-S\u00e1nchez G., Bordicchia M., Malcangi G., Pocognoli A., Morales-Segura M.A., Rothchild J., Rojas A. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. Eur. J. Pharmacol. 2014;742:158\u2013162. doi: 10.1016/j.ejphar.2014.08.029.", "ArticleIdList": ["10.1016/j.ejphar.2014.08.029", "25218903"]}, {"Citation": "Ludolph A.C., Bendotti C., Blaugrund E., Chio A., Greensmith L., Loeffler J.P., Mead R., Niessen H.G., Petri S., Pradat P.F., et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral Scler. 2010;11:38\u201345. doi: 10.3109/17482960903545334.", "ArticleIdList": ["10.3109/17482960903545334", "20184514"]}, {"Citation": "Benatar M. Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007;26:1\u201313. doi: 10.1016/j.nbd.2006.12.015.", "ArticleIdList": ["10.1016/j.nbd.2006.12.015", "17300945"]}, {"Citation": "Schulz S., H\u00e4ussler U., Mandic R., Heverhagen J.T., Neubauer A., D\u00fcnne A.A., Werner J.A., Weihe E., Bette M. Treatment with ozone/oxygen-pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas. Int. J. Cancer. 2008;122:2360\u20132367. doi: 10.1002/ijc.23382.", "ArticleIdList": ["10.1002/ijc.23382", "18224691"]}, {"Citation": "Bette M., N\u00fcsing R.M., Mutters R., Zamora Z.B., Menendez S., Schulz S. Efficiency of tazobactam/piperacillin in lethal peritonitis is enhanced after preconditioning of rats with O3/O2-pneumoperitoneum. Shock. 2006;25:23\u201329. doi: 10.1097/01.shk.0000187983.56030.dd.", "ArticleIdList": ["10.1097/01.shk.0000187983.56030.dd", "16369182"]}, {"Citation": "Bette M., Springmann V., Rossmann A., Weihe E., Sch\u00fctz B. Evidence for the absence of visceral pain in C57BL6/N mice subjected to therapeutically relevant O3/O2-pneumoperitoneum. Lab. Anim. 2017;51:17\u201323. doi: 10.1177/0023677216636832.", "ArticleIdList": ["10.1177/0023677216636832", "26946118"]}, {"Citation": "Ringer C., Weihe E., Schutz B. Calcitonin gene-related peptide expression levels predict motor neuron vulnerability in the superoxide dismutase 1-G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2012;45:547\u2013554. doi: 10.1016/j.nbd.2011.09.011.", "ArticleIdList": ["10.1016/j.nbd.2011.09.011", "21964254"]}, {"Citation": "Haenggeli C., Kato A.C. Differential vulnerability of cranial motoneurons in mouse models with motor neuron degeneration. Neurosci. Lett. 2002;335:39\u201343. doi: 10.1016/S0304-3940(02)01140-0.", "ArticleIdList": ["10.1016/S0304-3940(02)01140-0", "12457737"]}, {"Citation": "Menon P., Vucic S. The Upper Motor Neuron-Improved Knowledge from ALS and Related Clinical Disorders. Brain Sci. 2021;11:958. doi: 10.3390/brainsci11080958.", "ArticleIdList": ["10.3390/brainsci11080958", "PMC8392624", "34439577"]}, {"Citation": "Marques C., Burg T., Scekic-Zahirovic J., Fischer M., Rouaux C. Upper and Lower Motor Neuron Degenerations Are Somatotopically Related and Temporally Ordered in the sod1 mouse model of amyotrophic lateral sclerosis. Brain Sci. 2021;11:369. doi: 10.3390/brainsci11030369.", "ArticleIdList": ["10.3390/brainsci11030369", "PMC7998935", "33805792"]}, {"Citation": "Xu Z., Jung C., Higgins C., Levine J., Kong J. Mitochondrial degeneration in amyotrophic lateral sclerosis. J. Bioenerg. Biomembr. 2004;36:395\u2013399. doi: 10.1023/B:JOBB.0000041774.12654.e1.", "ArticleIdList": ["10.1023/B:JOBB.0000041774.12654.e1", "15377878"]}, {"Citation": "Argueti-Ostrovsky S., Alfahel L., Kahn J., Israelson A. All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. Cells. 2021;10:2438. doi: 10.3390/cells10092438.", "ArticleIdList": ["10.3390/cells10092438", "PMC8468417", "34572087"]}, {"Citation": "Parakh S., Atkin J.D. Protein folding alterations in amyotrophic lateral sclerosis. Brain Res. 2016;1648:633\u2013649. doi: 10.1016/j.brainres.2016.04.010.", "ArticleIdList": ["10.1016/j.brainres.2016.04.010", "27064076"]}, {"Citation": "Angenstein F., Niessen H.G., Goldschmidt J., Vielhaber S., Ludolph A.C., Scheich H. Age-dependent changes in MRI of motor brain stem nuclei in a mouse model of ALS. Neuroreport. 2004;15:2271\u20132274. doi: 10.1097/00001756-200410050-00026.", "ArticleIdList": ["10.1097/00001756-200410050-00026", "15371748"]}, {"Citation": "Hanisch U.K., Kettenmann H. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007;10:1387\u20131394. doi: 10.1038/nn1997.", "ArticleIdList": ["10.1038/nn1997", "17965659"]}, {"Citation": "Clarke B.E., Patani R. The microglial component of amyotrophic lateral sclerosis. Brain. 2020;143:3526\u20133539. doi: 10.1093/brain/awaa309.", "ArticleIdList": ["10.1093/brain/awaa309", "PMC7805793", "33427296"]}, {"Citation": "Schwartz M., Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol. 2010;6:405\u2013410. doi: 10.1038/nrneurol.2010.71.", "ArticleIdList": ["10.1038/nrneurol.2010.71", "20531383"]}, {"Citation": "Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. USA. 2008;105:15558\u201315563. doi: 10.1073/pnas.0807419105.", "ArticleIdList": ["10.1073/pnas.0807419105", "PMC2547419", "18809917"]}, {"Citation": "Chiu I.M., Chen A., Zheng Y., Kosaras B., Tsiftsoglou S.A., Vartanian T.K., Brown R.H., Carroll M.C. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. USA. 2008;105:17913\u201317918. doi: 10.1073/pnas.0804610105.", "ArticleIdList": ["10.1073/pnas.0804610105", "PMC2581614", "18997009"]}, {"Citation": "Banerjee R., Mosley R.L., Reynolds A.D., Dhar A., Jackson-Lewis V., Gordon P.H., Przedborski S., Gendelman H.E. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS ONE. 2008;3:e2740. doi: 10.1371/journal.pone.0002740.", "ArticleIdList": ["10.1371/journal.pone.0002740", "PMC2481277", "18648532"]}, {"Citation": "Staats K.A., Borchelt D.R., Tansey M.G., Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol. Neurodegener. 2022;17:11. doi: 10.1186/s13024-022-00515-1.", "ArticleIdList": ["10.1186/s13024-022-00515-1", "PMC8785449", "35073950"]}, {"Citation": "Kang J., Rivest S. MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis. J. Cell Biol. 2007;179:1219\u20131230. doi: 10.1083/jcb.200705046.", "ArticleIdList": ["10.1083/jcb.200705046", "PMC2140021", "18086918"]}, {"Citation": "Gasco S., Zaragoza P., Garc\u00eda-Redondo A., Calvo A.C., Osta R. Inflammatory and non-inflammatory monocytes as novel prognostic biomarkers of survival in SOD1G93A mouse model of Amyotrophic Lateral Sclerosis. PLoS ONE. 2017;12:e0184626. doi: 10.1371/journal.pone.0184626.", "ArticleIdList": ["10.1371/journal.pone.0184626", "PMC5591000", "28886177"]}, {"Citation": "Scassellati C., Galoforo A.C., Esposito C., Ciani M., Ricevuti G., Bonvicini C. Promising Intervention Approaches to Potentially Resolve Neuroinflammation and Steroid Hormones Alterations in Alzheimer\u2019s Disease and Its Neuropsychiatric Symptoms. Aging. Dis. 2021;12:1337\u20131357. doi: 10.14336/AD.2021.0122.", "ArticleIdList": ["10.14336/AD.2021.0122", "PMC8279527", "34341712"]}, {"Citation": "Leitner M., Menzies S., Lutz C. Working with ALS mice. Guidelines for preclinical testing and colony management. Jackson Lab. 2009"}, {"Citation": "Weydt P., Hong S.Y., Kliot M., M\u00f6ller T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport. 2003;14:1051\u20131054. doi: 10.1097/01.wnr.0000073685.00308.89.", "ArticleIdList": ["10.1097/01.wnr.0000073685.00308.89", "12802201"]}, {"Citation": "Ringer C., Tune S., Bertoune M.A., Schwarzbach H., Tsujikawa K., Weihe E., Sch\u00fctz B. Disruption of calcitonin gene-related peptide signaling accelerates muscle denervation and dampens cytotoxic neuroinflammation in SOD1 mutant mice. Cell Mol. Life Sci. 2017;74:339\u2013358. doi: 10.1007/s00018-016-2337-4.", "ArticleIdList": ["10.1007/s00018-016-2337-4", "27554772"]}, {"Citation": "Sever B., Ciftci H., DeMirci H., Sever H., Ocak F., Yulug B., Tateishi H., Tateishi T., Otsuka M., Fujita M., et al. Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2022;23:2400. doi: 10.3390/ijms23052400.", "ArticleIdList": ["10.3390/ijms23052400", "PMC8910198", "35269543"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "2", "Day": "23"}, {"Year": "2022", "Month": "3", "Day": "18"}, {"Year": "2022", "Month": "3", "Day": "18"}, {"Year": "2022", "Month": "3", "Day": "25", "Hour": "1", "Minute": "8"}, {"Year": "2022", "Month": "3", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["35328829", "PMC8950555", "10.3390/ijms23063403", "ijms23063403"]}}], "PubmedBookArticle": []}